Total
0
Shares
Immutep (ASX:IMM) - CEO, Marc Voigt (left) - The Market Herald
CEO, Marc Voigt (left)
Source: ShareCafe
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotechnology company Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a preliminary safety and efficacy review
  • The study is evaluating a combination of Immutep's lead product candidate, efti, with MSD's KEYTRUDA in patients with head, neck and lung cancers
  • Following the review and recommendation by the data monitoring committee, Immutep has begun recruiting an additional 13 second-line non-small cell lung cancer patients to form stage two of Part B
  • The trial is being conducted at 12 centres in Australia, Europe, the U.K. and the U.S.
  • Shares last traded at 31.5 cents

Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a recommendation from the data monitoring committee.

The biotechnology company will recruit an additional 13 patients with second-line non-small cell lung cancer (NSCLC) to form stage two of Part B.

It comes after a preliminary safety and efficacy review of stage one of Part B by the data monitoring committee.

The study is being conducted in collaboration with MSD, testing the efficacy of a combined treatment in patients with second line head and neck squamous cell carcinoma or NSCLC in first and second line.

Immutep's lead product candidate eftilagimod alpha, or simply efti, is being trialled with MSD's KEYTRUDA, or pembrolizumab.

The trial is being conducted at 12 centres in Europe, the U.K., the U.S. and Australia.

Part A enrolled patients with NSCLC and PD-X naive, Part B enrolled second-line NSCLC and PD-X refectory patients, and Part C will recruit second-line head and neck squamous cell carcinoma and PD-X naive patients.

Shares last traded at 31.5 cents.

IMM by the numbers
More From The Market Herald
Anatara Lifesciences (ASX:ANR) - CEO, Steven Lydeamore - The Market Herald

" Anatara Lifesciences (ASX:ANR) secures patent for animal health product

Anatara Lifesciences (ANR) has been granted an Australian patent covering the formulation for its animal health product, Detach.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald

" Recce Pharmaceuticals (ASX:RCE) advances new clinical trials

Recce Pharmaceuticals (RCE) is close to commencing human clinical trials for its topical burns treatment, RECCE 327.
Mayne Pharma (ASX:MYX) - CEO, Scott Richards - The Market Herald

" Mayne Pharma’s (ASX:MYX) oral contraceptive receives FDA approval

Mayne Pharma (MYX) and Mithra Pharmaceuticals have received approval for its combined oral contraceptive Nextstellis from the U.S. Food and Drug Administration (FDA).
Universal Biosensors (ASX:UBI) enters distribution deal with Wine & Beer Supply

" Universal Biosensors (ASX:UBI) enters distribution deal with Wine & Beer Supply

Universal Biosensors (UBI) has entered a deal with Wine & Beer Supply for the distribution of its wine testing device in the U.S.